Jakob Dupont - 30 Jun 2026 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: Director
Issuer ticker: PYXS
Reported as of: 30 Jun 2026
Net transaction value: -$107,100
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:30:46 UTC
Prior SEC filing: 11 Jun 2026
Next SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Jakob Dupont

Key filing fact

Jakob Dupont filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 02 Jul 2026.

Key facts

This page summarizes Jakob Dupont's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 16:30.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: -$107,100.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001553335 Primary reporting owner

Dupont Jakob

Relationship: Director
Address: C/O PYXIS ONCOLOGY, INC., 321 HARRISON AVENUE, 11TH FL. SUITE 1, BOSTON
Signature: /s/ Jitendra Wadhane, Attorney-in-Fact for Jakob Dupont
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PYXS transaction

Common Stock

Options Exercise

Transaction value
Shares: +35,000
Change %: +90%
Price: $1.60^*
Shares after: 73,741
Date: 30 Jun 2026
Ownership: Direct

PYXS transaction

Common Stock

Sale

Transaction value: $107,100
Shares: -35,000
Change %: -47%
Price: $3.06
Shares after: 38,741
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -35,000
Change %: -8.9%
Price: $0.000000^*
Shares after: 357,461
Date: 30 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $1.60
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025.

Footnote F2

Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4.

Footnote F3

The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36.

Footnote F4

Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).